Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 7, 2010, Pages 445-451

  Nishikawa, Tetsuo ^a   Matsuzawa, Yoko ^a   Suematsu, Sachiko ^a   Saito, Jun ^a   Omura, Masao ^a   Kino, Tomoshige ^b  

^a YOKOHAMA ROSAI HOSPITAL   (Japan)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Aldosterone; Angiotensin II type 1 receptor; Atorvastatin; CAS 134523 03 8; CYP11B2; Mesangial cells

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ATORVASTATIN; GLUCOSE; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ARTICLE; CELL COUNT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; HUMAN; HUMAN CELL; MESANGIUM CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEROIDOGENESIS; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; METABOLISM;

ALDOSTERONE; ANGIOTENSIN II; ANTICHOLESTEREMIC AGENTS; CYTOCHROME P-450 CYP11B2; DIABETIC NEPHROPATHIES; GLUCOSE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MESANGIAL CELLS; PYRROLES; RECEPTOR, ANGIOTENSIN, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77955397295     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296310     Document Type: Article

References (32)

1. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson, PW. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009;94:1853-78.
2. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 2008;74:22-36.
3. Vasudevan MM, Ballantyne CM. Advances in lipid testing and management in diabetics. Endocr Pract. 2009:1-38.
4. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J AmSoc Nephrol. 2006;17:2006-16.
5. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP, Group GSC. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin. 2003;19:615-7.
6. Jandeleit-Dahm K, Cao Z, Cox AJ, Kelly DJ, Gilbert RE, Cooper ME. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int. 1999;71 Suppl:S31-6.
7. Blanco S, Vaquero M, Gomez-Guerrero C, Lopez D, Egido J, Romero R. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. AmJ Hypertens. 2005;18:557-65.
8. Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-b, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol. 2008;295:F53-9.
9. Schlondorff D, Banas B. The mesangial cell revisited: no cell is an island. J AmSoc Nephrol. 2009;20:1179-87.
10. Siragy HM, Xue C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol. 2008;93:817-24.
11. Wu O, Liang X, Dai Y, Liu H, Zang Y, Guo Z, et al. Aldosterone biosynthesis in extra adrenal tissues. Chinese Med J. 1999;112:414-8.
12. Nishikawa T, Suematsu S, Saito J, Soyama A, Ito H, Kino T, et al. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol. 2005;96:309-16.
13. Martinez D, Oestreicher E, Roubsanthisuk W, Yao T, Ricchiuti V, Williams GK. Angiotensin II, aldosterone, and the caveolae: IV. Aldosterone content of the kidney after adrenalectomy. J Hypertens. 2002;20:s115. Abstract#P0457.
14. Mohaupt MG. The role of adrenal steroidogenesis in arterial hypertension. Endocr Dev. 2008;13:133-44.
15. Hostetter TH, Rosenberg ME, Ibrahim HN, Juknevicius I. Aldosterone in renal disease. Curr Opin Nephrol Hypertens. 2001;10:105-10.
16. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063-68.
17. Hene RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982;21:98-101.
18. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit- Faisant B, Carayon A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999;99:2694-701.
19. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem. 1998;273:4883-91.
20. Kayes-Wandover KM, White PC. Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab. 2000;85:2519-25.
21. TakedaY, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology. 2000;141:1901-4.
22. Bichu P, Nistala, Khan A, Sowers JR, Whaley-Connell A. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag. 2009;5:129-40.
23. Shah IM, Mackay SP, McKay GA. Therapeutic strategies in the treatment of diabetic nephropathy - a translational medicine approach. Curr Med Chem. 2009;16:997-1016.
24. Hakki T, Bernhardt R. CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacol Ther. 2006;111:27-52.
25. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20:953-70.
26. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999;100:2131-4.
27. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59:646-54.
28. Briones AM, Rodriguez-Criado N, Hernanz R, Garcia-Redondo AB, Rodrigues-Diez RR, Alonso MJ, et al. Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension. 2009;54:142-9.
29. Maczewski M, Maczewska J, Duda M. Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors. Br J Pharmacol. 2008;154:1640-8.
30. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Treating to New Targets, I., Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2:1131-9.
31. Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, et al. Effect of captril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985;26:1617-20.
32. Brenner BM, Parving HH, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.